Ryan, C.J., Smith, M.R., de Bono, J.S., Molina, A., Logothetis, C.J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J.M., Ng, S., Carles, J., Mulders, P.F., Basch, E., Small, E.J., Saad, F., Schrijvers, D., Van Poppel, H., Mukherjee, S.D., Suttmann, H., Gerritsen, W.R., Flaig, T.W., George, D.J., Yu, E.Y., Efstathiou, E., Pantuck, A., Winquist, E., Higano, C.S., Taplin, M.E., Park, Y., Kheoh, T., Griffin, T., Scher, H.I. and Rathkopf, D.E. (2013) Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy. The New England Journal of Medicine, 368, 138-148.
https://doi.org/10.1056/NEJMoa1209096

has been cited by the following article:

• TITLE: Switching of GnRH Agent from Agonist to Antagonist in Patients with Castration-Resistant Prostate Cancer

  AUTHORS: Shinji Fukui, Yasushi Nakai, Yoriaki Kagebayashi, Shoji Samma

  KEYWORDS: CRPC, GnRH Antagonist, PSA, FSH

  JOURNAL NAME: Open Journal of Urology, Vol.6 No.12, December 21, 2016

  ABSTRACT: Objectives: To evaluate the efficacy of alteration from gonadotropin-releasing hormone (GnRH) agonist to antagonist in patients with castration-resistant prostate cancer (CRPC). Methods: Fourteen patients with CRPC were switched from GnRH agonist to GnRH antagonist. CRPC was defined as 3 consecutive rises of PSA values under androgen deprivation therapy despite a testosterone level at the castration level. No patient underwent a change in oral anti-androgen agent or any additional therapy. Patients who showed increase of the PSA value within 10% or showed decrease in the PSA value compared to the baseline were defined as responders. We measured serum PSA, testosterone, follicular stimulating hormone (FSH), and leutenizing hormone (LH) at the time of alteration and 3 months after alteration. Results: The mean age at diagnosis was 74.8 ± 6.3 years with a mean initial PSA level of 537.3 ± 999.1 ng/mL. The mean age at alteration to GnRH antagonist was 81.4 years with a mean PSA level of 28.6 ng/mL. Two out of 14 patients (14%) were judged as responders based on PSA after alteration to GnRH antagonist, although they did not show any further reduction of the serum testosterone level (remain less than 0.03). Six patients showed further reduction of the serum FSH level after alteration; however, they showed no PSA response (from 46.4 ± 42.6 to 69.4 ± 70.3). Conclusions: The switch from GnRH agonist to GnRH antagonist affected 14% of the patients (2 out of 14 patients) with CRPC at 3 months based on PSA. Larger and longer-term studies are required to determine the efficacy of alteration to GnRH antagonist in patients with CRPC.